ASCO, American Society of Clinical Oncology

5. 6. 2004 - 8. 6. 2004, New Orleans, USA

Konferenční abstrakta:

Aktivní účast z České republiky na ASCO 2004:

1. M. Hajduch, M. Palacova, R. Trojanec, L. Dusek, K. Petrakova, K. Spackova, R. Obermannova, M. Galova, S. Blazkova, R. Vyzula:
Anthracycline based chemotherapy decreases amplification status of Her-2/neu and topoisomerase II alpha genes in locally advanced breast cancer.
Meeting: 2004 ASCO Annual Meeting, Category: Molecular Targets

2. P. Lemez, J. Stejskal, S. Cahova, V. Benesova, D. Dvorakova, J. Fisar, L. Slavicek:
Healers, providers of complementary/ alternative medicine, may be dangerous to all oncological patients including themselves.
Meeting: 2004 ASCO Annual Meeting, Abstract No: 6137, Category: Health Services Research
3. Z. Kleibl, J. Novotny, P. Pohlreich, M. Zikan, P. Cinek, M. Janatova, L. Petruzelka; Charles University, First Faculty of Medicine, Prague, Czech Republic:
Low frequency of CHEK2 1100delC mutation in breast cancer patients and hereditary breast cancer families in the Czech Republic.
Meeting: 2004 ASCO Annual Meeting, Category: Cancer Genetics
4. M. Zimovjanova, Z. Kleibl, V. Sykora, J. Novotny, L. Petruzelka:
DPD mutations and expression in patients with serious toxicity during therapy with 5FU based regimens: National project.
Meeting: 2004 ASCO Annual Meeting, Abstract No: 3118, Category:Pharmacogenomics
5. L. Petruzelka, M. Zimovjanova:
Fulvestrant in postmenopausal women with metastatic breast cancer progressing on prior endocrine therapy - results from a compassionate use program.
Meeting: 2004 ASCO Annual Meeting, Abstract No: 730, Category: Metastatic Breast Cancer
6. B. Melichar, K. Melicharova, J. Cerman:
Hepatic arterial infusion (HAI) in gastric cancer (GC) liver metastases (mets): A pooled analysis of the reported results.
Meeting: 2004 ASCO Annual Meeting, Abstract No: 4211, Category: Esophageal, Gastric, or Small Bowel Cancer
7. M. Pesek, V. Spidlen, P. Mukensnabl:
Induction chemotherapy before lung cancer resection: Experiences and perspectives.
Meeting: 2004 ASCO Annual Meeting, Abstract No: 7329, Category: Non-Small Cell Lung Cancer
8. J. Prausova, R. Lohynska, B. Malinova, J. Novotny:
Prognostic factors in preoperative radiotherapy for locally advanced rectal cancer.
Meeting: 2004 ASCO Annual Meeting, Abstract No: 3647, Category: Colorectal Cancer (including liver metastases)
9. K. Petrakova, H. Koukalová, R. Soumarová, M. Palácová, S. Bla?kova, R. Vyzula:
Relative risk (RR) of second malignancies (SM) in patients treated by "risk" radiotherapy (RT) or "risk" RT plus chemotherapy (CT) in comparison with patients treated by CT ± "non risk RT" for Hodgkin's disease (HD).
Meeting: 2004 ASCO Annual Meeting, Abstract No: 6695, Category: Lymphoma
10. A. Dmoszynska, J. Kloczko, M. Rokicka, A. Hellmann, I. Spicka:
CERA (Continuous Erythropoiesis Receptor Activator) in patients with multiple myeloma: An exploratory phase I-II dose escalation study.
Meeting: 2004 ASCO Annual Meeting, Abstract No: 6552, Category: Multiple Myeloma
11. I. Kocakova, M. Svoboda, K. Klocova, S. Spelda, I. Kocak, P. Slampa, I. Penka, R. Sefr, R. Vyzula:
Combined therapy of locally advanced rectal adenocarcinoma with capecitabine and concurrent radiotherapy.
Meeting: 2004 ASCO Annual Meeting, Abstract No: 3720, Category: Colorectal Cancer (including liver metastases)
12. T. Robak, A. B. Skotnicki, J. Mayer, V. Vukovic, S. Weitman:
Interim safety summary of alemtuzumab vs. chlorambucil as front-line therapy for patients with progressive B-cell chronic lymphocytic leukemia (BCLL).
Meeting: 2004 ASCO Annual Meeting, Abstract No: 6563, First Author: T. Robak,Category: Leukemia
13. K.-H. Schlingensiepen, A. Bischof, T. Egger, M. Hafner, H. Herrmuth, P. Jachimczak, M. Kielmanowicz, M. Niewel, E. Zavadova, G. Stauder:
The TGF-beta1 antisense oligonucleotide AP 11014 for the treatment of non-small cell lung, colorectal and prostate cancer: Preclinical studies.
Meeting: 2004 ASCO Annual Meeting, Abstract No: 3132, Category: Gene Therapy/Antisense Strategies
14. F. Janku, J. Novotny, Z. Kleibl, P. Tesarova, L. Petruzelka, B. Matous, M. Safanda, M. Zemanova, P. Mares:
Validation of Cytokeratin 19, Mammaglobin A and B in detection of breast cancer cells in the bone marrow using a nested reverse transcriptase polymerase chain reaction (RT-PCR) assay.
Meeting: 2004 ASCO Annual Meeting, Abstract No: 9672, Category: Molecular Diagnostics and Staging
15. M. Gottfried, R. Ramlau, M. Krzakowski, L. Novakova, A. Szczesna, J. Barcelo, R. Perng, D. Grunenwald:
Vinorelbine (NVB)-based triplet with ifosfamide (IFO) and cisplatin (NIP) as induction chemotherapy (CT) to increase resection rate in marginally unresectable non-small cell lung cancer (NSCLC) patients (pts).
Meeting: 2004 ASCO Annual Meeting, Abstract No: 7165, Category: Non-Small Cell Lung Cancer
16. K. Oesterlind, J. M. Sanchez, P. Zatloukal, M. C. Perry, J. T. Hamm, C. P. Belani, E. S. Kim, J. F. Vansteenkiste, E. Felip, M. Berton:
A phase I/II dose escalation trial of EPO906 every 3 weeks in patients with non-small cell lung cancer (NSCLC).
Meeting: 2004 ASCO Annual Meeting, Abstract No: 7248, Category: Non-Small Cell Lung Cancer
17. G. Giaccone, C. Debruyne, E. Felip, M. Millward, G. D'Addario, L. Thiberville, L. Rome, P. Zatloukal, C. Legrand:
Phase III study of BEC2/BCG vaccination in limited disease small cell lung cancer (LD-SCLC) patients, following response to chemotherapy and thoracic irradiation (EORTC 08971, the SILVA study).
Meeting: 2004 ASCO Annual Meeting, Abstract No: 7020, Category: Small Cell Lung Cancer
18. M. G. Pfreundschuh, L. Trümper, D. Ma, A. Österborg, R. Pettengell, M. Trneny, L. Shepherd, J. Waleswski, P.-L. Zinzani, M. Loeffler:
Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab - early stopping after the first interim analysis.
Meeting: 2004 ASCO Annual Meeting Abstract No: 6500 Category: Lymphoma
19. R. P. Abratt, A. Szczesna, K. Mattson, M. Wernli, P. Reiterer, R. Hui, J. Lizon, O. Bertetto, M. Reck, E. H. Tan:
Vinorelbine (NVB)-carboplatin (CBDCA) vs non-platinum doublets in inoperable non-small cell lung cancer (NSCLC) patients (pts)-final results of the Glob 2 phase III with patient benefit analysis.
Meeting: 2004 ASCO Annual Meeting, Category: Non-Small Cell Lung Cancer

Typ akce: Onkologie

Web: http://www.asco.org

  • Sdílejte na:
    • Facebook
    • Twitter
    • Del.icio.us
    • Digg
    • Google
    • Reddit
    • StumbleUpon
    • Live